Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05186883
Other study ID # IBCE_Parathyr
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date March 1, 2022
Est. completion date December 31, 2023

Study information

Verified date January 2022
Source Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Contact Andrei Hancharou, Dr
Phone +375296248972
Email hancharou@ibp.org.by
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The idea of the project is to develop a method of treatment of postoperative hypoparathyroidism using cultured allogenic parathyroid cells.


Description:

The cells will be isolated and cultured from the parathyroid gland of brain-dead organ donors. Cells will be tested for the immunophenotype, viability, sterility and the production of parathyroid hormone. Cells will be co-cultured with the patients T-cells and the expression of perforin and granzyme B proteins will be assayed as well as the apoptosis/viability of parathyroid cells. Prepared cells will be used to treat the patients with postoperative hypoparathyroidism. The safety, tolerability and clinical efficacy will be studied.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Clinical diagnosis of postoperative hypoparathyroidism - Decreased PTH concentrations in blood serum - The patient can read, understand, follow the examination procedures and complete, if necessary, the required documentation - Written informed consent Exclusion Criteria: - The presence of any malignant tumor within the last 5 years - Acute or chronic diseases in the stage of decompensation - Chronic infectious diseases: HIV, viral hepatitis B, C, tuberculosis - Patients who are pregnant, breastfeeding, or fertile patients who are not using adequate contraceptive methods - Chronic and protracted mental disorders, all diseases with the presence of the syndrome of dependence on alcohol, drugs and psychoactive substances, any other condition that makes the patient unable to understand the nature, extent and possible consequences of the study or, in the opinion of the researcher, prevents the patient from observing and performing protocol - Patients are unable or unwilling to give written informed consent and / or follow research procedures - Any other medical condition that, in the opinion of the investigator, may be associated with an increased risk to the patient or may affect the outcome or evaluation of the study

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Allogenic parathyroid cells
Allogenic parathyroid cells
Other:
Standard treatment according to the Clinical protocols
Standard treatment of postoperative hypoparathyroidism according to the Clinical protocols

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus Belarusian State Medical University

Outcome

Type Measure Description Time frame Safety issue
Primary PTH in blood serum The concentration of PTH in blood serum 3 month
Primary PTH in blood serum The concentration of PTH in blood serum 6 month
Primary PTH in blood serum The concentration of PTH in blood serum 1 year
Primary Adverse effects associated with the therapy Determination of adverse effects associated with the therapy 1 month
Primary Adverse effects associated with the therapy Determination of adverse effects associated with the therapy 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05579782 - Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy N/A
Completed NCT04281875 - Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy. N/A